Reviewed by Michael Gill, B. Sc.
25 Weight Loss Clinical Trials Near Me
Top Hospitals for Weight Loss Clinical Trials
Image of Pennington Biomedical Research Center in Louisiana.
Pennington Biomedical Research Center
Baton Rouge
3Active Trials
18All Time Trials for Weight Loss
2001First Weight Loss Trial
Image of Drexel University Center for Weight, Eating and Lifestyle Science in Pennsylvania.
Drexel University Center for Weight, Eating and Lifestyle Science
Philadelphia
2Active Trials
2All Time Trials for Weight Loss
2019First Weight Loss Trial
Top Cities for Weight Loss Clinical Trials
Weight Loss Clinical Trials by Phase of Trial
Phase 1 Weight Loss Clinical Trials
1Active Weight Loss Clinical Trials
1Number of Unique Treatments
1Number of Active Locations
Remune
Weight Loss Clinical Trials by Age Group
< 18 Weight Loss Clinical Trials
1Active Weight Loss Clinical Trials
HealthTRAC
Top Treatments for Weight Loss Clinical Trials
Treatment Name
Active Weight Loss Clinical Trials
All Time Trials for Weight Loss
First Recorded Weight Loss Trial
Active Intervention Group
2
2
2016
Weight Management Intervention
2
4
2018
Exercise
2
17
2004
Time restricted eating and calorie restriction
1
1
2022
Intervention Arm
1
1
2023
Recently Completed Studies with FDA Approved Treatments for Weight Loss
Treatment
Year
Sponsor
Botox 200 UNT Injection
2021
Vanderbilt University Medical Center
Orlistat
2018
Emory University

What Are Weight Loss Clinical Trials?

Maintaining a healthy lifestyle requires you to be at your ideal weight according to your body mass index (BMI). Losing weight is also not an immediate process; it takes time and relies on healthy eating habits and physical activity for long-term management.

Overweight people are at an increased risk of developing serious diseases and health conditions, such as high blood pressure, diabetes, heart diseases, and overall poor quality of life.

Many weight loss clinical trials focus on drug therapies to treat weight loss or develop healthy eating and physical activity programs to combat weight gain.

Why Is Weight Loss Being Studied Through Clinical Trials?

According to the CDC, nearly three-quarters of the American population is overweight or obese, and nearly 160 million Americans are on a diet anytime. Moreover, Americans spend approximately $70 million on weight-loss plans and supplements. Not to mention being overweight is a major health hazard, and even a total of 5 to 10% weight loss can contribute to health benefits like improved blood pressure, cholesterol, and blood sugars.

What Are The Types of Treatments Available For Weight Loss?

Research on weight loss and obesity is ongoing. Currently, weight loss clinical trials focus on using drugs to help regulate appetite and hunger signaling. Therapeutic interventions have shown two new drugs, semaglutide and tirzepatide, to reduce body fat successfully.

In this, semaglutide is an anti-diabetic drug formulated as an injectable solution for subcutaneous administration. According to the New England Journal of Medicine, participants who were administered 2.4mg of semaglutide once weekly reduced body fat.

Tirzepatide is a similar drug that showed significant results in a 72-week trial. The participants with obesity were given 10mg or 15mg of tirzepatide once weekly and showed a continuous reduction in body weight.

What Are Some Recent Breakthrough Clinical Trials For Weight Loss?

There have been several landmark studies involving weight loss in recent years. Some of the most recent studies are:

2021: Healthy Weight Loss Maintenance - in this study, participants with obesity who did not have diabetes were enrolled in an 8-week low-calorie diet and were assigned 4 random strategies, such as a moderate-to-vigorous–intensity exercise program plus placebo (exercise group); treatment with liraglutide (3.0 mg per day) plus usual activity (liraglutide group); exercise program plus liraglutide therapy (combination group); or placebo plus usual activity (placebo group). In the end, 195 participants had a mean decrease in body weight of 13.1 kg.

2020: Drug Therapy in Obesity - this study focuses on using sodium-glucose co-transporter-2 (SGLT-2) inhibitors, amylin mimetics, leptin analogs, ghrelin antagonists, and centrally acting agents to suppress appetite. However, sufficient evidence is lacking in the routine use of these drugs.

Who Are Some Of The Key Opinion Leaders / Researchers / Institutions Conducting Weight Loss Clinical Trial Research?

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIDDK conducts clinical trials to identify new ways to prevent, detect, or treat overweight and obesity. The studies include identifying new drugs, the role of bacteria and metabolism, and physical activity in treating and managing obesity.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: October 5th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA. 2014 Feb 26;311(8):806-14. doi: 10.1001/jama.2014.732. https://pubmed.ncbi.nlm.nih.gov/245702442 Barlow SE; Expert Committee. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics. 2007 Dec;120 Suppl 4:S164-92. https://pubmed.ncbi.nlm.nih.gov/180556513 Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008 Oct 9;359(15):1577-89. doi: 10.1056/NEJMoa0806470. Epub 2008 Sep 10. https://pubmed.ncbi.nlm.nih.gov/187840904 Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):854-65. Erratum in: Lancet 1998 Nov 7;352(9139):1558. https://pubmed.ncbi.nlm.nih.gov/97429775 Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012 Jun;55(6):2005-23. doi: 10.1002/hep.25762. https://pubmed.ncbi.nlm.nih.gov/224887646 Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000 Aug 12;321(7258):405-12. https://pubmed.ncbi.nlm.nih.gov/109380487 Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, Hu FB, Hubbard VS, Jakicic JM, Kushner RF, Loria CM, Millen BE, Nonas CA, Pi-Sunyer FX, Stevens J, Stevens VJ, Wadden TA, Wolfe BM, Yanovski SZ; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Obesity Society. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2985-3023. doi: 10.1016/j.jacc.2013.11.004. Epub 2013 Nov 12. Erratum in: J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):3029-3030. https://pubmed.ncbi.nlm.nih.gov/242399208 Spear BA, Barlow SE, Ervin C, Ludwig DS, Saelens BE, Schetzina KE, Taveras EM. Recommendations for treatment of child and adolescent overweight and obesity. Pediatrics. 2007 Dec;120 Suppl 4:S254-88. Review. https://pubmed.ncbi.nlm.nih.gov/180556549 Gormally J, Black S, Daston S, Rardin D. The assessment of binge eating severity among obese persons. Addict Behav. 1982;7(1):47-55. https://pubmed.ncbi.nlm.nih.gov/708088410 Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA. 2012 Feb 1;307(5):491-7. doi: 10.1001/jama.2012.39. Epub 2012 Jan 17. https://pubmed.ncbi.nlm.nih.gov/22253363